INGN and Yuwell collaborate to expand and enhance Inogen's innovation pipeline through R&D collaboration and accelerate the entry of Inogen's brand into the Chinese market.
Needham analyst Michael Matson has maintained their neutral stance on INGN stock, giving a Hold rating on January 14.Invest with Confidence: ...
INGN's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products.
On the eve of theArab Health Exhibition, Yuwell Medical held its 2025 Global Core Partner Conference in Dubai, and announced ...
The 50th Arab Health Exhibition opened on Monday at the Dubai World Trade Center featuring over 4000 exhibitors from various countries including mo ...